PTGX - Protagonist Therapeutics Inc logo

Protagonist Therapeutics Inc

PTGX

Protagonist Therapeutics develops peptide-based therapies for conditions like plaque psoriasis, polycythemia vera, and obesity. Its pipeline includes oral and injectable treatments targeting inflammatory and rare diseases, focusing on unmet medical needs.

โš•๏ธ Healthcare NASDAQ Listed 2016 $ USD
$1,000 invested 10 years ago โ†’$4,831today

Score Overview

1 Year
Score
Net Growth+362.98%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth+11x
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score7.8
Net Growth+372.61%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth+20x
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth+11x
Net Trend60%
Net Income Consistency
Rev Growthโ€”
Rev Trend63%
Revenue Consistency
All Time
Scoreโ€”
Net Growth+11x
Net Trend60%
Net Income Consistency
Rev Growthโ€”
Rev Trend63%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Protagonist Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. PTGX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-20
$ 121.40โ€”
1 Year2025-11-20
$ 84.20+44.18%
5 Years2021-11-19
$ 35.03+246.56%
10 Years2016-11-18
$ 25.13+383.09%
All Time2016-08-11
$ 11.70+10x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

  • Revenue
  • Net Income
  • Cash
Year
TTM$ 551M$ 342M$ 800M
2025$ 46M-$ 130M$ 567M
2024$ 434M$ 275M$ 418M
2023$ 60M-$ 78M$ 341M
2022$ 26M-$ 123M$ 237M
2021$ 27M-$ 125M$ 326M
2020$ 28M-$ 66M$ 305M
2019-$ 77M$ 133M
2018$ 30M-$ 38M$ 128M
2017$ 20M-$ 36M$ 144M
IPO2016$ 0.00-$ 37M$ 77M
PTGX - Protagonist Therapeutics Inc logo

Protagonist Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 28M to $ 46M and net income went from -$ 66M to -$ 130M. Revenue increased in 3 of those 5 years; net income in 4.

Protagonist Therapeutics Inc currently holds a 5-year HDB Score of 7.8 out of 10. How the HDB Score is calculated.

Membership

Explore PTGX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,184 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies